Serum free light chain quantitative assays: Dilemma of a biomarker

Journal of Clinical Laboratory Analysis

Volumn 32, Issue 2, 2018, Pages

  Cigliana, Giovanni ^a   Gulli, Francesca ^b   Napodano, Cecilia ^b   Pocino, Krizia ^b   De Santis, Elena ^a   Colacicco, Luigi ^b   Cordone, Iole ^a   Conti, Laura ^a   Basile, Umberto ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

comparative study; free light chains; multiple myeloma

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN; TUMOR MARKER;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FREELITE ASSAY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; N LATEX ASSAY; QUALITY CONTROL; QUANTITATIVE ASSAY; REPRODUCIBILITY; SERUM FREE LIGHT CHAIN QUANTITATIVE ASSAY; STANDARDIZATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; STATISTICAL MODEL;

AGED; BIOMARKERS; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REPRODUCIBILITY OF RESULTS;

EID: 85018296977     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.22243     Document Type: Article

References (34)

1. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485-1493.
2. Tosi P, Tomassetti S, Merli A, Polli V. Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Ther Adv Hematol. 2013;4:37-41.
3. Anderson KC, Alsina M, Atanackovic D, et al. NCCN guidelines insights: multiple myeloma, version 3. J Natl Compr Canc Netw. 2016;14:389-400.
4. Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood. 2012;120:927-928.
5. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147:22-42.
6. Bird JM, Cavenagh J, Samson D, Mehta A, Hawkins P, Lachmann H. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125:681-700.
7. Bird JM, Owen RG, D'sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154:32-75.
8. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117:4701-4705.
9. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-224.
10. Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28:981-992.
11. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548.
12. Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep. 2013;5:4.
13. Basile U, Mussap M. Rationale and prospects of serum immunoglobulin free light chain (FLC) determination in chronic inflammatory disease. Biochim Clin. 2013;37:357-364.
14. Bosmann M, Kößler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med. 2010;48:1419-1422.
15. Jacobs JF, Tate JR, Merlini G. Is accuracy of serum free light chain measurement achievable? Clin Chem Lab Med. 2016;54:1021-1030.
16. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev. 2009;30:131-140.
17. Jacobs JFM, Hoedemakers RMJ, Teunissen E, Van der Molen RG, Te Velthuis H. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta. 2012;413:1708-1709.
18. Vercammen M, Meirlaen P, Broodtaerts L, Broek IV, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta. 2011;412:1798-1804.
19. Carr-Smith HD, Jenner EL, Evans JA, Harding SJ. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. Clin Chem Lab Med. 2016;54:997-1003.
20. Te Velthuis H, Knop I, Stam P, et al. N Latex FLC—new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49:1323-1332.
21. Lock RJ, Saleem R, Roberts EG, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem. 2013;50(Pt 3):255-261.
22. Hoedemakers RM, Pruijt JF, Hol S, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med. 2011;50:489-495.
23. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem. 2012;49:450-455.
24. Campbell JP, Heaney JL, Shemar M, et al. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin Chem Lab Med. 2017;55:424-434.
25. Tate J, Mollee P. Towards improved measurement of serum free light chains: clinical and laboratory issues. Biochim Clin. 2013;37:395-404.
26. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-e346.
27. Clinical and Laboratory Standards Institute (CLSI). User verification of performance for precision and trueness. CLSI document EP15-A2. Wayne, PA: CLSI, April 2006.
28. CLSI. EP09-A3-Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline, 3rd edn, 2013;33:1-98.
29. Mahmood S, Wassef NL, Salter SJ, et al. Comparison of free light chain assays: Freelite and N latex in diagnosis, monitoring, and predicting survival in light chain amyloidosis. Am J Clin Pathol. 2016;146:78-85.
30. Kennard A, Hawley C, Tate J, et al. Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis. Clin Chem Lab Med. 2016;54:1045-1052.
31. Di Noto G, Cimpoies E, Dossi A, et al. Polyclonal versus monoclonal immunoglobulin-free light chains quantification. Ann Clin Biochem. 2015;52(Pt 3):327-336.
32. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
33. Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL. Monitoring free light chains in serum using mass Spectrometry. Clin Chem Lab Med. 2016;54:1073-1083.
34. Braga F, Infusino I, Dolci A, Panteghini M. Biological variation of free light chains in serum. Clin Chim Acta. 2013;415:10-11.